Progesterone Receptor (PGR) content of
breast cancer tissue is an important parameter in the prediction of prognosis
and response to endocrine therapy. PGR clone 16 is directed against the human
progesterone receptor molecule. A prokaryotic recombinant protein, corresponding
to the N-terminal region of the A form of human progesterone receptor, was used
as the immunogen. Antibody characterization studies demonstrated that PGR Clone
16 reacts with both A and B forms of human progesterone receptor in Western
blotting procedure.